Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus best supportive care versus placebo plus best supportive care in previously treated metastatic gastric or gastroesophageal junction adenocarcinoma
2008-005964-15Phase 3Completed
- Sponsor
- ImClone Systems
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Ramucirumab + BSC with Placebo + BSC (2 arms). Primary endpoint: Overall survival. Started Dec 2009; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2008-005964-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005964-15.